## UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 18, 2019

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Sunesis Pharmaceuticals, Inc.

File No. 000-51531 - CF#37336

Sunesis Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 6, 2014.

Based on representations by Sunesis Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.46 through March 6, 2024 Exhibit 10.47 through March 6, 2024

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Vanessa Countryman Acting Secretary